2nd Annual Symposium on Advanced Therapeutics for Brain Metastasis: Moving the Needle and Controversies at the Cutting Edge


2nd Annual Symposium on Advanced Therapeutics for Brain Metastasis: Moving the Needle and Controversies at the Cutting Edge Banner

Add to Calendar 2nd Annual Symposium on Advanced Therapeutics for Brain Metastasis: Moving the Needle and Controversies at the Cutting Edge 3/7/2024 8:00:00 AM 3/7/2024 5:00:00 PM America/New_York For More Details: https://mskcc.cloud-cme.com/course/courseoverview?EID=43108 Description: This didactic and case-based educational program will provide a comprehensive update on the latest advancements in the treatment and research of brain metastasis. Tailored for clinicians and translational scientists, this symposium will cover central nervous system (CNS)-specific outcomes from both molecular and traditional cancer histology viewpoints. Recent evidence for brain metastasis activity wil... Online false MM/DD/YYYY


Date & Location
Thursday, March 7, 2024, 8:00 AM - 5:00 PM, Online

Specialties
Specialties - Breast Medical Oncology, Genitourinary Oncology, Gynecologic Oncology, Medical Oncology, Neuro-Oncology, Neuroradiology, Neurosurgery, Oncology and Hematology, Radiation Oncology, Solid Tumor Oncology, Thoracic Medical Oncology

Overview

This didactic and case-based educational program will provide a comprehensive update on the latest advancements in the treatment and research of brain metastasis. Tailored for clinicians and translational scientists, this symposium will cover central nervous system (CNS)-specific outcomes from both molecular and traditional cancer histology viewpoints. 

Recent evidence for brain metastasis activity will be highlighted for key medical targets (e.g. Her2, EGFR, KRAS, CDK, BRAF, and ALK), and leading experts will review brain metastasis prognosis across the cancers commonly resulting in this (lung, breast, and melanoma).

A dedicated session on recent developments in local therapy will review the role of laser interstitial thermal therapy, brachytherapy, and external beam radiation techniques.

In recognition of the many complex treatment interactions imposed by multimodality treatment often necessary, a 'Key Controversies' session will speak to major areas of clinical difficulty, for example, how to distinguish on recurrent disease from radiation necrosis on imaging studies, when to change therapy with CNS-only progressive disease, which leptomeningeal metastasis interventions are currently worthwhile, and special considerations regarding steroid use and radiation therapy for patients requiring immunotherapy.

Key scientists will discuss promising translational and clinical trial approaches including targeting metastasis-initiating cells and window-of-opportunity studies.

Given the special challenge of early detection, a dedicated session will cover state-of-the art molecular imaging techniques, the evidence for/against imaging surveillance in standard-risk cancers, and the current state of liquid biopsy.

A roundtable discussion with participants from several centers will share their experiences and best practices with multidisciplinary team care and discuss areas for improvement. Finally, a multidisciplinary tumor board will review multifaceted cases, highlighting the interplay of various treatment options.

This symposium is set to be an exclusively live virtual experience with ample opportunity to network and engage with speakers and other participants.

Target Audience

This symposium is intended for neurosurgeons, radiation oncologists, neurologists and neuro-oncologists, physicians in training, and other allied health professionals who treat and manage patients with metastatic disease.

Online Syllabus

Attendees will receive access to an online syllabus after the symposium, which includes select PDFs of presentations (slides) and video recordings of the lectures.

Objectives
At the conclusion of this symposium, learners will be able to:

  1. Describe the current multimodal landscape of brain metastasis treatment
  2. Identify key clinical controversies in brain metastasis management
  3. Discuss barriers to improved treatments and potential research strategies (e.g. limited CNS activity of systemic anti-cancer treatments, side effects of local treatments, limited survival, and unclear endpoints)

Registration

This symposium is complimentary for all to attend. Please complete registration through the 'Register' tab above. Detailed Zoom access and participation instructions will be provided to registrants prior to the start of the program. We kindly request that those who register also plan to attend. If you are registered for this symposium and are unable to attend, please notify us by emailing [email protected].

Industry professionals may attend MSK CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities. For more information, please visit our Help 


Accreditation

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of 7.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC/CC Recognition Statements

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

  • 7.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program; and
  • 7.75 Lifelong Learning (CME) credits in the American Board of Pathology’s (ABPath) Continuing Certification program. 

It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABPath MOC/CC credit.